FDA grants priority review status to Gilead's hepatitis C drug
June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.
The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.
The FDA set a review date of Dec. 8 for the drug, Gilead said.
Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.
Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.